Mednax Inc (MD): they purchased southeast anas. in charlo...

they purchased southeast anas. in charlotte - over

IPO$ · 2014-01-29T20:31:42.3970000Z

they purchased southeast anas. in charlotte - over 100 doctors

Play Episode

7min

Proactive - Interviews for investors

Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Proactive - Interviews for investors

Ecora Resources sees strong 2024 results as cobalt, copper growth drive strategy

Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) CEO Marc Bishop Lafleche takes Proactive's Stephen Gunnion through the company’s full-year 2024 financial results and the strategic progress made across its royalty portfolio. Lafleche reported a strong performance in 2024 despite challenging market conditions, citing volume growth at Voisey’s Bay as a key highlight, even as cobalt prices approached 50-year lows. He said, “Since year-end, actually, it's amazing how quickly things can change,” pointing to a 60–70% year-to-date increase in cobalt prices. Ecora’s focus remained on expanding its base metals exposure, with 80% of its portfolio now weighted toward critical minerals, particularly copper. The company emphasised that royalties offer long-term exposure, with copper making up 50% of its estimated net asset value. Lafleche also detailed major portfolio drivers for 2025, including expected volume growth from Voisey’s Bay, Mantos Blancos, and the newly acquired Mimbula Copper Stream. Looking further ahead, he highlighted potential upside from de-bottlenecking and tailings processing projects at Mantos Blancos and progress at Santo Domingo, Phalaborwa, and Piauí. For more updates on Ecora Resources and other companies in the critical minerals space, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #EcoraResources #CriticalMinerals #RoyaltyInvesting #Copper #Cobalt #VoiseysBay #MantosBlancos #MiningNews #BaseMetals #ProactiveInvestors #Commodities #ElectricFuture #SustainableMining

Proactive - Interviews for investors

AuKing prepares for gold mining at Mt Freda site

AuKing Mining Ltd managing director Paul Williams talked with Proactive about the company's latest update on its Cloncurry Project in Queensland, focusing on the Mt Freda deposit. Williams confirmed that with Orion Resources nearing acquisition completion, AuKing is preparing to restart mining operations at the historical Mt Freda gold mine. Williams highlighted Mt Freda as a top target for redevelopment due to its existing mining lease and approvals, as well as a current resource estimate of around 100,000oz. "We really don't want to start a mining operation unless we've got reserves in the resource estimate," he explained, outlining the company’s aim to confirm and expand those figures through an upcoming drilling program. In addition to resource verification, AuKing is evaluating two processing options: existing vat leaching pits and a nearby cavern in-leach circuit at Lorena. Williams also noted the broader potential in the surrounding six square kilometre Mt Freda Complex, which contains multiple historical deposits, hinting at further exploration upside. Drilling is expected to start within weeks of the acquisition's financial close in April, with results anticipated in the months following. Williams described the program as "a fascinating exercise," indicating renewed momentum behind the restart strategy. For more updates from AuKing Mining Ltd and other resource sector insights, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #AuKingMining #MtFreda #GoldMining #ASXAKN #CloncurryProject #ResourceDrilling #MiningRestart #QueenslandMining #JuniorMining #GoldExploration #MiningInvestment #ASXResources #OrionResources

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Followers	225
Posts	12731
Boards Moderated	0
Alias Born	04/13/2007

Volume:	104
Day Range:
Bid:
Ask:
Last Trade Time:	4:00:58 AM EDT
Total Trades:	5

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

MD Detailed Quote

Recent MD News

More MD News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent MD News

Go Ad-Free